Patents by Inventor Deborah Luxenberg

Deborah Luxenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding antibodies against PD-1
    Patent number: 8088905
    Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: January 3, 2012
    Assignees: Wyeth, MedImmune Limited
    Inventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Viia Valge-Archer, John Andrews, Caroline Russell
  • METHODS OF UPMODULATING ADAPTIVE IMMUNE RESPONSE USING ANTI-PD1 ANTIBODIES
    Publication number: 20100028330
    Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
    Type: Application
    Filed: March 16, 2009
    Publication date: February 4, 2010
    Applicants: Medimmune Limited, Wyeth
    Inventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Viia-Valge Archer, John Andrews, Caroline Russell
  • Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
    Patent number: 7521051
    Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: April 21, 2009
    Assignees: MedImmune Limited, Wyeth
    Inventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Viia Valge-Archer, John Andrews, Caroline Russell
  • Antibodies against PD-1
    Patent number: 7488802
    Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: February 10, 2009
    Assignees: Wyeth, MedImmune Limited
    Inventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Vila Valge-Archer, John Andrews, Caroline Russell
  • Antibodies against PD-1 and uses therefor
    Publication number: 20080311117
    Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
    Type: Application
    Filed: August 17, 2007
    Publication date: December 18, 2008
    Inventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Viia Valge-Archer, John Andrews, Caroline Russell
  • Methods of using antibodies against human IL-22
    Publication number: 20070258982
    Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.
    Type: Application
    Filed: February 20, 2007
    Publication date: November 8, 2007
    Inventors: Lynette Fouser, Martin Hegen, Deborah Luxenberg, Margot O'Toole
  • Antibodies against pd-1 and uses therefor
    Publication number: 20060210567
    Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
    Type: Application
    Filed: December 22, 2003
    Publication date: September 21, 2006
    Inventors: Mary Collins, Clive Wood, Beatriz Carreno, Deborah Luxenberg, Jason Jussif, Laura Carter, Frances Bennett, Viia-Valge Archer, Caroline Russell
  • Antibodies against PD-1 and uses therefor
    Publication number: 20040213795
    Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
    Type: Application
    Filed: December 22, 2003
    Publication date: October 28, 2004
    Applicants: Wyeth, Cambridge Antibody Technology
    Inventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Viia Valge-Archer, John Andrews, Caroline Russell